Alseres Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alseres Pharmaceuticals

ALSE 0.00500

0.0%

Oct 18 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	4/16/2007 12:45:48 PM
	of 975

Hope, Hype or real potential???? 11:58AM Boston Life Sciences announces extension of Phase I/IIa Trial to 9 mg dosage level (BLSI) 2.85 +0.12 : Co announces that clinical data on its lead nerve repair therapy, Cethrin, were presented in the Neurotrauma and Critical Care Scientific Session at the 75th Annual Meeting of the American Association of Neurological Surgeons in Washington, DC. "The preliminary results in this study show that Cethrin may offer great promise for restoring sensory and motor function for patients with new cases of acute SCI," stated Dr. Mark Hurtt, BLSI's Chief Medical Officer. "We have extended the Phase IIa trial to include a 9 mg dose. Currently, three patients have been enrolled at this level and we expect the enrollment at this dosage extension to continue to the 3rd quarter of 2007. Additionally, based on the positive findings to-date in the Phase I/II trial, we are drafting a protocol for a Phase IIb/III study. We plan to meet with the FDA and with Health Canada and plan to initiate this trial in North America by the end of this year or early 2008."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next